Women Are Leading the Way in Life Sciences

IDbyDNA Expands Scientific Advisory Board with Infectious Disease, Sequencing & FDA Leaders

On the heels of its appointment of Next-Generation Sequencing (NGS) leader Neil Gunn as CEO, IDbyDNA announces the addition of several notable leaders to their Scientific Advisory Board, including Dr. Adrian Egli, Dr. Tamara V. Feldblyum, Dr. Karl Voelkerding, Dr. Christopher Woods, and Dr. Stephen Young.

Taking the Guesswork Out of Diagnostics

Next-Generation Sequencing and the Diagnosis of Disease

IDbyDNA Welcomes Biotech Top Talents Wendy Chang and Reza Anayat to Its Company Leadership Team

In support of their mission to become the Precision Metagenomics company in infectious disease testing and management, IDbyDNA has filled…

DARPA to Develop Hand-Held Disease Detection Device

Gunn named CEO at IDbyDNA

BioSpace Movers & Shakers

IDbyDNA Appoints Next-Gen Sequencing Executive Neil Gunn as New CEO

Infectious disease continues to be a leading cause of illness, morbidity and mortality around the world. In the fight to better understand all pathogens, including the SARS-CoV-2 lineage and its mutations, IDbyDNA, the pioneer in Precision Metagenomics, is focused on broadening availability for its Next-Generation Sequencing (NGS) targeted products. With that, the company has appointed NGS leader Neil Gunn as its new CEO to drive the next phase of growth.

CareDx Q1 Revenues up 76 Percent

IDbyDNA’s Metagenomics Suite Future-Proofs Labs for Coming Pathogen Crises

IDbyDNA Boosts Its Global Metagenomic Respiratory Pathogen/AMR Surveillance Solution to Now Offer Enhanced SARS-CoV-2 Variant Interpretation

How Variant Surveillance Could Drive a Sequencing Boom

CareDx CEO: ‘We’re Not Just a One-Trick Pony’

CareDx Adds Infectious Disease Focus to Transplant Diagnostics with IDbyDNA

Under 30 Alum Mammoth Biosciences To Develop Diagnostics For Department Of Defense

Mammoth, IDbyDNA Get DARPA Funds for CRISPR Diagnostics Development

DARPA to Fund CRISPR Diagnostics Using Mammoth, IDbyDNA Technologies

Genetic Engineering and Biotechnology News

The Future Is Now: How Metagenomics Could Affect Infectious Disease Diagnostics

The fight against Sars-CoV-2 in 2021: What’s next?

DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech

+ read more

IDbyDNA Announces Engagement in United States Defense Advanced Research Projects Agency (DARPA) Program to Detect Threats Using Gene Editing Technologies

CareDx, IDbyDNA Partner to Develop Infectious Disease Dx for Transplant Patients

CareDx Announces AlloID and Exclusive Partnership with IDbyDNA

IDbyDNA Receives Accreditation from College of American Pathologists (CAP)

Illumina, IDbyDNA Flesh Out Sequencing-Based Respiratory Tests

Startups Apply Powerful Genetic Sequencing Technique to Covid-19 Battle

Illumina and IDbyDNA Launch Test That May Find Next Epidemic

IDbyDNA and Illumina Launch New Rapid Test to Better Detect Respiratory Co-Infections and Identify Antibiotic-Resistant Pathogens

Healthcare Execs Discuss Working During a Pandemic

IDbyDNA Commercializing Explify Platform for Comprehensive Pathogen Detection and Surveillance

AWS and 1 Strategy Case Study: IDbyDNA and Application Migration, HIPAA Compliance, and DevOps Workflows

GenomeWeb Covers News of IDbyDNA’s Announcement this Week of SARS-CoV-2 Detection with the Gatot Soebroto Army Hospital in Indonesia

Metagenomics As a Tool To Diagnose and Understand COVID-19

IDbyDNA Chief Medical Officer Dr. Robert Schlaberg was just featured in an interview by Technology Networks, where he discusses how next-generation sequencing and metagenomics-based testing with the Explify Platform can address respiratory infections like SARS-CoV-2.

IDbyDNA to Help Indonesian Government Fight COVID-19 Pandemic

Metagenomics Innovator Delivers First NGS-Based SARS-CoV-2 Detection for Gatot Soebroto Army Hospital.

IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

IDbyDNA announces a global strategic partnership with Illumina to bring next-generation sequencing based workflows to the global microbiology market.

IDbyDNA Raises $20 Million in Series B Financing to Continue Advancements in Infectious Disease Diagnosis and Pathogen Identification

IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification, and interpretation of microorganisms and their role in human health, today announced the raise of $20 million in its Series B financing led by ARTIS Ventures and joined by Genesys Capital and others.

Novel Wuhan Coronavirus Detectable with IDbyDNA Explify Respiratory Test

IDbyDNA, Inc., a metagenomics technology company setting the standard for detection, identification and interpretation of microorganisms and their role in human health, today announced that its currently available Explify Respiratory test can detect 2019-nCoV in addition to over 900 other viral, bacterial, fungal and parasitic pathogens.